Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 179 results for transplantation

  1. Single-port laparoscopic nephrectomy (IPG414)

    Evidence-based recommendations on single-port laparoscopic nephrectomy. This involves removing the kidney using several small incisions (laparoscopy).

    Interventional procedures guidance
    Published
    23 November 2011
    View recommendations

    Sections for IPG414

  2. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)

    Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    23 March 2011
    View recommendations

    Sections for TA218

  3. Belatacept for the prevention of organ rejection in kidney transplantation [ID87]

    Discontinued Reference number: GID-TAG239

    Technology appraisal guidance
    Discontinued

  4. Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)

    Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.

    Highly specialised technologies guidance
    Published
    28 March 2022
    View recommendations

    Sections for HST18

  5. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA370

  6. Bortezomib monotherapy for relapsed multiple myeloma (TA129)

    Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.

    Technology appraisal guidance
    Published
    23 October 2007
    View recommendations

    Sections for TA129

  7. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued Reference number: GID-TA10306

    Technology appraisal guidance
    Discontinued

  8. HIV testing: encouraging uptake (QS157)

    This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    7 September 2017
    View quality statements

    Sections for QS157

  9. Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis (IPG746)

    Evidence-based recommendations on tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis. This involves inserting a catheter under the skin in the abdomen to drain excess fluid when needed, at home or in community care. The aim is to reduce the need for hospital admissions and improve quality of life.

    Interventional procedures guidance
    Published
    23 November 2022
    View recommendations

    Sections for IPG746

  10. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

    Evidence summary
    Published
    22 December 2015

  11. Fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction (IPG205)

    Evidence-based recommendations on fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction. This involves inserting a tube with a flexible camera through small cuts in the mother's abdomen to identify and open any blockage.

    Interventional procedures guidance
    Published
    24 January 2007
    View recommendations

    Sections for IPG205

  12. Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]

    Discontinued Reference number: GID-TAG232

    Technology appraisal guidance
    Discontinued

  13. Reducing the risk of complications of anticancer treatment in children and young people, and in adults diagnosed with lymphoma:- Randomised studies should investigate primary prophylaxis of neutropenic sepsis in 2 populations: children and young people (aged under 18) having treatment for solid tumours or haematological malignancies, or stem cell transplantation; and adults (aged 18 and older) diagnosed with lymphoma. The studies should compare the effectiveness of fluoroquinolone antibiotics given alone, fluoroquinolone antibiotics given together with G-CSF preparations, and G-CSF preparations given alone. Outcome measures should include overall mortality, infectious episodes and adverse events. In addition, quality of life should be determined using quantitative and qualitative methods. The resulting data should be used to develop a cost-effectiveness analysis comparing these 3 forms of prophylaxis in children and young people having anticancer treatment, and in adults diagnosed with lymphoma.

    treatment for solid tumours or haematological malignancies, or stem cell transplantation; and adults (aged 18 and older) diagnosed with...

    Research recommendation
    Published
    9 June 2015

  14. Hand allotransplantation (IPG383)

    Evidence-based recommendations on hand transplant surgery (allotransplantation). This involves transplanting a hand from a recently deceased donor onto the amputated stump.

    Interventional procedures guidance
    Published
    23 March 2011
    View recommendations

    Sections for IPG383

  15. NICE encourages further research into CXL using riboflavin and UVA for keratoconus and keratectasia, especially epithelium-on (transepithelial) CXL and the combination (CXL-plus) procedures. Details of the techniques used should be clearly described. Reported outcomes should include visual acuity, corneal topography and quality of life. Data on long-term outcomes for all types of CXL using riboflavin and UVA for keratoconus and keratectasia would be useful – specifically data about prevention of progression to corneal transplantation and about repeat procedures and their efficacy.

    useful – specifically data about prevention of progression to corneal transplantation and about repeat procedures and their efficacy....

    Research recommendation
    Published
    9 June 2015